GlassScriptPhysician profile
Ashlie Arthur
NPI 1558701847
$3,034.95
in general payments reported to CMS, 2019-2025
28 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $290 · 2021: $333 · 2022: $648 · 2023: $589 · 2024: $484 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $809.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $303.95 | 2020-2023 | Glassia, Cuvitru |
| Astrazeneca Pharmaceuticals LP | $297.80 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.14 | 2019-2023 | Stiolto Respimat, Ofev |
| Insmed, INC. | $136.23 | 2024-2025 | Arikayce |
| Grifols USA, LLC | $120.80 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $115.59 | 2024-2025 | Tezspire |
| Axsome Therapeutics, INC. | $108.28 | 2023 | Sunosi |
| Mylan Specialty L.P. | $90.09 | 2019-2023 | Yupelri |
| Pfizer INC. | $83.91 | 2019-2023 | |
| Inspire Medical Systems, INC. | $78.45 | 2024-2025 | Inspire |
| Advanced Respiratory, INC | $70.17 | 2020-2021 | |
| Baxter Healthcare | $67.20 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $66.26 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $60.59 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $53.68 | 2022-2023 | |
| Verona Pharma, INC. | $48.13 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $44.31 | 2024 | Zemaira |
| Regeneron Healthcare Solutions, INC. | $43.49 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $23.69 | 2023 | |
| Ani Pharmaceuticals, INC. | $21.79 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $18.78 | 2021 | |
| Resmed Corp | $17.58 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $15.81 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.64 | 2019 | |
| Shire North American Group INC | $14.32 | 2019 | |
| Viatris Specialty LLC | $14.06 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlie Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.